½ÃÀ庸°í¼­
»óǰÄÚµå
1826002

¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ¹× CRISPR Áø´Ü ½ÃÀå : ¿ëµµº°, ±â¼úº°, Àå¼Òº°, ¾÷°èº°, Á¦Ç°º°, À̱×Á¦Å¥Æ¼ºê ÄÁ¼³ÅÏÆ® °¡À̵å ÷ºÎ(2026-2030³â)

Gene Editing & CRISPR Diagnostic Markets. By Application, Technology, Place, Industry & Product with Executive and Consultant Guides. 2026 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Howe Sound Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 465 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º¸°í¼­ °³¿ä

À¯ÀüÀÚ ÆíÁýÀº ÈûÀ» Áõ°¡Çϰí ÀÖ½À´Ï´Ù. CRISPR°ú À¯»çÇÑ µµ±¸´Â »ý¸í °øÇÐÀÇ ¸ðµç ºÐ¾ß¿¡¼­ »õ·Î¿î ¿ëµµ¸¦ ã½À´Ï´Ù. ±×°ÍÀº »ì¾ÆÀÖ´Â Àΰ£ ¼¼Æ÷ÀÇ À¯ÀüÀÚ¸¦ º¯È­½ÃÄÑ ÀÇ·á¿¡ Àû¿ëÇÏ´Â °ÍÀ¸·Î ½ÃÀ۵˴ϴÙ. ºÒÄ¡ÀÇ Áúº´Àº ÀÌ¹Ì Ä¡À¯µÇ¾ú½À´Ï´Ù. ´õ ¸¹Àº Áúº´ÀÌ ÁøÇà ÁßÀÔ´Ï´Ù. ±Þ¼ºÀå ³ë¼±ÀÌ °¡¼ÓµÇ°í ÀÖ½À´Ï´Ù. ¿©·¯ »ê¾÷¿¡¼­ »õ·Î¿î ¿ëµµ°¡ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ±â¼úÀÇ ºñ¾àÀû Áøº¸ ¶§¸¶´Ù »õ·Î¿î ±âȸ°¡ ź»ýÇϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ ±âȸ¸¦ ÀÌÇØÇÕ´Ï´Ù. ´Ü±âÀû, Àå±âÀûÀ¸·Î ¹«¾ùÀÌ ¿¹»óµÇ´ÂÁö ¾Ë ¼ö ÀÖ½À´Ï´Ù. Çö½ÇÀûÀÎ ¼ºÀå ¿¹ÃøÀ» ÆÄ¾ÇÇÕ´Ï´Ù. ´ç»çÀÇ Á¶»ç¸¦ ÅëÇØ ±Í»ç´Â Á¶Á÷ÀÇ Àü¹®°¡°¡ µË´Ï´Ù.

¿äû¿¡ µû¶ó ¸ðµç º¸°í¼­ µ¥ÀÌÅ͸¦ ¿¢¼¿ Çü½ÄÀ¸·Î Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå °¡À̵å

Á¦2Àå ¼Ò°³¿Í ½ÃÀå Á¤ÀÇ

  • Á¶»ç ¹æ¹ý
  • À¯ÀüÀÚ ÆíÁýÀ̶õ ¹«¾ùÀΰ¡
  • CRISPRÀÇ ¿¹
  • ¿°»öü, À¯ÀüÀÚ, Èļº À¯ÀüÇÐ
  • ½ÃÀå Á¤ÀÇ
  • ½ÃÁ¡ : ÀÇ·áºñ ÁöÃâ

Á¦3Àå ½ÃÀå ±¸Á¶

  • ½ÃÀå ±¸Á¶Ä¡·áÁ¦
    • ¿¬±¸°³¹ß(R&D)±â¾÷
    • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • Á¦³×¸¯ ÀǾàǰ Á¦Á¶¾÷ü
    • ÁÖ¿ä Á¦¾à ȸ»ç
    • °è¾à¿¬±¸±â°ü(CRO)
    • °è¾àÁ¦Á¶Á¶Á÷(CMO)
    • Àü¹®ÀǾàǰȸ»ç
    • ÀǾàǰ ÆÇ¸Å¾÷ÀÚ
    • ¼Ò¸Å ¾à±¹
    • µµ¸Å¾÷ü
    • ¿Â¶óÀÎ ¾à±¹
    • ÀÇ·á±â¼ú±â¾÷
    • ¾à±¹ ÇýÅà °ü¸®ÀÚ(PBM)
    • ÀÓ»ó ½ÇÇè½Ç
    • ÀÇ·á±â±â ±â¾÷
    • ±ÔÁ¦±â°ü
  • ½ÃÀå ±¸Á¶Áø´Ü
    • Çмú¿¬±¸±â°ü
    • Áø´Ü ½ÃÇè °³¹ßÀÚ
    • °èÃø±â±â °ø±ÞÀÚ
    • ¾àǰ ¹× ½Ã¾à Á¦Á¶¾÷ü
    • º´¸® °ø±ÞÀÚ
    • µ¶¸³°è ÀÓ»ó ½ÇÇè½Ç
    • °ø°øÀÇ ±¹¸³/Áö¿ª ¿¬±¸¼Ò
    • º´¿ø °Ë»ç½Ç
    • ÀÓ»ó ½ÇÇè½Ç
    • °¨»ç±â°ü
    • ÀÎÁõ±â°ü

Á¦4Àå ½ÃÀå µ¿Çâ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ

Á¦5Àå À¯ÀüÀÚ ÆíÁýÀÇ ÃÖ±Ù µ¿Çâ

Á¦6Àå ÁÖ¿ä ±â¾÷

  • ÁÖ¿ä ±â¾÷ - º» ÀåÀÇ Á߿伺°ú »ç¿ë¹ý
  • 10x Genomics, Inc.
  • 4D Molecular Therapeutics
  • Abeona Therapeutics
  • Acrigen Biosciences
  • Adarx Pharmaceuticals
  • Adverum Biotechnologies
  • Affini-T Therapeutics
  • Agilent
  • Arbor Biotechnologies
  • Arcturus Therapeutics
  • Axxam
  • Beam Therapeutics
  • Beckman Coulter Diagnostics(Danaher)
  • Becton, Dickinson and Company
  • Binx Health
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Bluebird Bio
  • Caribou Biosciences
  • Cell Microsystems
  • Cellenion(BICO)
  • Century Therapeutics
  • Chroma Medicine
  • Creative Biogene
  • Crispr Therapeutics
  • Editas Medicine
  • ERS Genomics
  • FASMAC
  • Genscript Biotech
  • Illumina
  • Inscripta
  • Intellia Therapeutics
  • J&J Innovative Medicine
  • Locus Biosciences
  • Mammoth Biosciences
  • Metagenomi
  • Myllia Biotechnology
  • Namocell
  • NRGene
  • Oxford Biomedica
  • Poseida Therapeutics
  • Precision Biosciences
  • Prime Medicine
  • Proof Diagnostics
  • Regeneron Pharmaceuticals
  • Revvity
  • Roche Diagnostics
  • Sangamo Therapeutics
  • Sherlock Biosciences
  • Thermo Fisher Scientific
  • Twist Bioscience
  • VedaBio
  • Verve Therapeutics
  • Vivlion
  • Wave Life Science

Á¦7Àå ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå

  • ±¹°¡º° ¼¼°è ½ÃÀå °³¿ä
  • ¿ëµµº° ¼¼°è ½ÃÀå - °³¿ä
  • ±â¼úº° ¼¼°è ½ÃÀå - °³¿ä
  • Àå¼Òº° ¼¼°è ½ÃÀå - °³¿ä
  • ¾÷°èº° ¼¼°è ½ÃÀå - °³¿ä
  • Á¦Ç°º° ¼¼°è ½ÃÀå - °³¿ä

Á¦8Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå- ¿ëµµº°

  • ¼¼Æ÷ÁÖ
  • ½Ä¹°
  • µ¿¹°
  • ¼¼Æ÷¿ä¹ý
  • À¯ÀüÀÚ Ä¡·á
  • Áø´Ü
  • ¿¬±¸
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå - ±â¼úº°

  • CRISPR
  • Talens
  • ZFN
  • ¸Þ°¡´ºÅ¬·¹¾ÆÁ¦
  • ±âŸ

Á¦10Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå- Àå¼Òº°

  • »ýü³»
  • »ýü¿Ü
  • ü¿Ü

Á¦11Àå À¯ÀüÀÚ ÆíÁý ½ÃÀå - ¾÷°èº°

  • Á¦¾à
  • ÀÓ»ó
  • Çмú
  • ¼öʱâ°ü
  • ±âŸ

Á¦12Àå ¼¼°èÀÇ À¯ÀüÀÚ ÆíÁý ½ÃÀå- Á¦Ç°º°

  • ±â±â
  • ¼¼Æ÷
  • ½Ã¾à
  • ±âŸ

Á¦13Àå ºÎ·Ï

JHS

Report Overview:

Gene Editing is moving from strength to strength. CRISPR and similar tools are finding new uses in every area of biotechnology. It started with Medical applications by changing genes in living human cells. Uncurable diseases have already being cured. More are on the way. A fast growth path is accelerating. New applications are developing in multiple industries. New opportunities are arising with every technological breakthrough. Understand the various opportunities. Find out what is expected in the near term and the long term. Get a handle on realistic growth expectations. Our research makes you the expert in your organization.

All report data is available in Excel format on request.

Table of Contents

1. Market Guides

  • 1.1. Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. Methodology
    • 2.1.1. Methodology
    • 2.1.2. Sources
    • 2.1.3. Authors
  • 2.2. What is Gene Editing?
  • 2.3. The CRISPR Example
    • 2.3.1. What is CRISPR?
    • 2.3.2. The CRISPR Family
  • 2.4. Chromosomes, Genes and Epigenetics
    • 2.4.1. Chromosomes
    • 2.4.2. Genes
    • 2.4.3. Epigenetics
  • 2.5. Market Definition
    • 2.5.1. Revenue Market Size
  • 2.6. Perspective: Healthcare Spending
    • 2.6.1. Global Healthcare Spending
    • 2.6.2. Spending on Healthcare and Pharmaceuticals
    • 2.6.3. Spending on Diagnostics
    • 2.6.4. Important Role of Insurance for Medical Services

3. Market Structure

  • 3.1. Market Structure Therapeutics
    • 3.1.1. Research and Development (R&D) Companies
    • 3.1.2. Biotechnology Companies
    • 3.1.3. Generic Drug Manufacturers
    • 3.1.4. Big Pharmaceuticals
    • 3.1.5. Contract Research Organizations (CROs)
    • 3.1.6. Contract Manufacturing Organizations (CMOs)
    • 3.1.7. Specialty Pharmaceutical Companies
    • 3.1.8. Pharmaceutical Distributors
    • 3.1.9. Retail Pharmacies
    • 3.1.10. Wholesalers
    • 3.1.11. Online Pharmacies
    • 3.1.12. Health Technology Companies
    • 3.1.13. Pharmacy Benefit Managers (PBMs)
    • 3.1.14. Clinical Laboratories
    • 3.1.15. Medical Device Companies
    • 3.1.16. Regulatory Bodies
  • 3.2. Market Structure Diagnostics
    • 3.2.1. Academic Research Lab
    • 3.2.2. Diagnostic Test Developer
    • 3.2.3. Instrumentation Supplier
    • 3.2.4. Chemical/Reagent Supplier
    • 3.2.5. Pathology Supplier
    • 3.2.6. Independent Clinical Laboratory
    • 3.2.7. Public National/regional Laboratory
    • 3.2.8. Hospital Laboratory
    • 3.2.9. Physicians Office Lab (POLS)
    • 3.2.10. Audit Body
    • 3.2.11. Certification Body

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Cell Therapy
    • 4.1.2. Gene Therapy
    • 4.1.3. The New Agriculture
    • 4.1.4. Genetics and Cell Metabolism
  • 4.2. Factors Limiting Growth
    • 4.2.1. The Cost Curve
    • 4.2.2. Time and Trials
    • 4.2.3. The Price Barrier

5. Recent Developments in Gene Editing

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. VedaBio Licenses Diagnostic CRISPR Technology
  • 5.3. YolTech Therapeutics Raises $45 Million in Series B Funding
  • 5.4. Prime Editing Breakthrough Corrects Genetic Deficiency
  • 5.5. Arbor Biotechnologies Announces First Patient Dosed
  • 5.6. CRISPR Therapeutics Reports Positive Data for Liver-Targeted Therapy
  • 5.7. Lilly to acquire Verve Therapeutics
  • 5.8. Personalized CRISPR Therapy for Infant with Rare Genetic Disease
  • 5.9. New CRISPR Diagnostic Test Detects Pathogens Without Amplification
  • 5.10. OraSure Technologies Acquires Sherlock Biosciences
  • 5.11. CRISPR tool allows for remote-controlled gene-editing
  • 5.12. CRISPR Making Sweeter Tomatoes
  • 5.13. Researchers Create gene-edited prawns
  • 5.14. Gene Editing Corrects Cystic Fibrosis
  • 5.15. Gene Editing Reverses Heart Disease In Mice
  • 5.16. CRISPR gene editing to change healthcare?
  • 5.17. CrisprBits Collaborates With MolBio Diagnostics
  • 5.18. Sherlock Bioscience to Launch Free AI-Based Operating System
  • 5.19. Sherlock Biosciences to Acquire Sense Biodetection
  • 5.20. CRISPR Enzyme Discovery Opens New Applications
  • 5.21. Sherlock Biosciences Adds Ambient Amplification to Toolkit
  • 5.22. Rice University Adapts CRISPR Enzyme
  • 5.23. Princeton Group Develops Cas13 Assay for Point-of-Care Use
  • 5.24. Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC System
  • 5.25. Sherlock Biosciences Raises $80M
  • 5.26. Broad Institute Considers CRISPR Respiratory Panels to Replace PCR
  • 5.27. Medix Biochemica Acquires MyPols Biotec
  • 5.28. Mammoth Biosciences High-Throughput CRISPR-Based COVID Test Gets EUA

6. Key Companies

  • 6.1. Key Companies - Importance and How to Use This Section
    • 6.1.1. Importance of These Players
    • 6.1.2. How to Use This Section
  • 6.2. 10x Genomics, Inc.
  • 6.3. 4D Molecular Therapeutics
  • 6.4. Abeona Therapeutics
  • 6.5. Acrigen Biosciences
  • 6.6. Adarx Pharmaceuticals
  • 6.7. Adverum Biotechnologies
  • 6.8. Affini-T Therapeutics
  • 6.9. Agilent
  • 6.10. Arbor Biotechnologies
  • 6.11. Arcturus Therapeutics
  • 6.12. Axxam
  • 6.13. Beam Therapeutics
  • 6.14. Beckman Coulter Diagnostics (Danaher)
  • 6.15. Becton, Dickinson and Company
  • 6.16. Binx Health
  • 6.17. bioMerieux Diagnostics
  • 6.18. Bio-Rad Laboratories, Inc
  • 6.19. Bluebird Bio
  • 6.20. Caribou Biosciences
  • 6.21. Cell Microsystems
  • 6.22. Cellenion (BICO)
  • 6.23. Century Therapeutics
  • 6.24. Chroma Medicine
  • 6.25. Creative Biogene
  • 6.26. Crispr Therapeutics
  • 6.27. Editas Medicine
  • 6.28. ERS Genomics
  • 6.29. FASMAC
  • 6.30. Genscript Biotech
  • 6.31. Illumina
  • 6.32. Inscripta
  • 6.33. Intellia Therapeutics
  • 6.34. J&J Innovative Medicine
  • 6.35. Locus Biosciences
  • 6.36. Mammoth Biosciences
  • 6.37. Metagenomi
  • 6.38. Myllia Biotechnology
  • 6.39. Namocell
  • 6.40. NRGene
  • 6.41. Oxford Biomedica
  • 6.42. Poseida Therapeutics
  • 6.43. Precision Biosciences
  • 6.44. Prime Medicine
  • 6.45. Proof Diagnostics
  • 6.46. Regeneron Pharmaceuticals
  • 6.47. Revvity
  • 6.48. Roche Diagnostics
  • 6.49. Sangamo Therapeutics
  • 6.50. Sherlock Biosciences
  • 6.51. Thermo Fisher Scientific
  • 6.52. Twist Bioscience
  • 6.53. VedaBio
  • 6.54. Verve Therapeutics
  • 6.55. Vivlion
  • 6.56. Wave Life Science

7. The Global Market for Gene Editing

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Application - Overview
    • 7.2.1. Table - Global Market by Application
    • 7.2.2. Chart - Global Market by Application - Base/Final Year Comparison
    • 7.2.3. Chart - Global Market by Application - Base Year
    • 7.2.4. Chart - Global Market by Application - Final Year
    • 7.2.5. Chart - Global Market by Application - Share by Year
    • 7.2.6. Chart - Global Market by Application - Segment Growth
  • 7.3. Global Market Technology - Overview
    • 7.3.1. Table - Global Market by Technology
    • 7.3.2. Chart - Global Market by Technology - Base/Final Year Comparison
    • 7.3.3. Chart - Global Market by Technology - Base Year
    • 7.3.4. Chart - Global Market by Technology - Final Year
    • 7.3.5. Chart - Global Market by Technology - Share by Year
    • 7.3.6. Chart - Global Market by Technology - Segment Growth
  • 7.4. Global Market Type - Overview
    • 7.4.1. Table - Global Market by Type
    • 7.4.2. Chart - Global Market by Type - Base/Final Year Comparison
    • 7.4.3. Chart - Global Market by Type - Base Year
    • 7.4.4. Chart - Global Market by Type - Final Year
    • 7.4.5. Chart - Global Market by Type - Share by Year
    • 7.4.6. Chart - Global Market by Type - Segment Growth
  • 7.5. Global Market Industry - Overview
    • 7.5.1. Table - Global Market by Industry
    • 7.5.2. Chart - Global Market by Industry - Base/Final Year Comparison
    • 7.5.3. Chart - Global Market by Industry - Base Year
    • 7.5.4. Chart - Global Market by Industry - Final Year
    • 7.5.5. Chart - Global Market by Industry - Share by Year
    • 7.5.6. Chart - Global Market by Industry - Segment Growth
  • 7.6. Global Market Product - Overview
    • 7.6.1. Table - Global Market by Product
    • 7.6.2. Chart - Global Market by Product - Base/Final Year Comparison
    • 7.6.3. Chart - Global Market by Product - Base Year
    • 7.6.4. Chart - Global Market by Product - Final Year
    • 7.6.5. Chart - Global Market by Product - Share by Year
    • 7.6.6. Chart - Global Market by Product - Segment Growth

8. Gene Editing Markets - By Application

  • 8.1. Cell Line
    • 8.1.1. Table Cell Line - by Country
    • 8.1.2. Chart - Cell Line Growth
  • 8.2. Plant
    • 8.2.1. Table Plant - by Country
    • 8.2.2. Chart - Plant Growth
  • 8.3. Animal
    • 8.3.1. Table Animal - by Country
    • 8.3.2. Chart - Animal Growth
  • 8.4. Celll Therapy
    • 8.4.1. Table Cell Therapy - by Country
    • 8.4.2. Chart - Cell Therapy Growth
  • 8.5. Gene Therapy
    • 8.5.1. Table Gene Therapy - by Country
    • 8.5.2. Chart - Gene Therapy Growth
  • 8.6. Diagnostics
    • 8.6.1. Table Diagnostics - by Country
    • 8.6.2. Chart - Diagnostics Growth
  • 8.7. Research
    • 8.7.1. Table Research - by Country
    • 8.7.2. Chart - Research Growth
  • 8.8. Other Application
    • 8.8.1. Table Other Application - by Country
    • 8.8.2. Chart - Other Application Growth

9. Global Gene Editing Markets - by Technology

  • 9.1. Crispr
    • 9.1.1. Table Crispr - by Country
    • 9.1.2. Chart - Crispr Growth
  • 9.2. Talens
    • 9.2.1. Table Talens - by Country
    • 9.2.2. Chart - Talens Growth
  • 9.3. ZFN
    • 9.3.1. Table ZFN - by Country
    • 9.3.2. Chart - ZFN Growth
  • 9.4. Meganuclease
    • 9.4.1. Table Meganuclease - by Country
    • 9.4.2. Chart - Meganuclease Growth
  • 9.5. Other Technology
    • 9.5.1. Table Other Technology - by Country
    • 9.5.2. Chart - Other Technology Growth

10. Gene Editing Markets - by Place

  • 10.1. In Vivo
    • 10.1.1. Table In Vivo - by Country
    • 10.1.2. Chart - In Vivo Growth
  • 10.2. Ex Vivo
    • 10.2.1. Table Ex Vivo - by Country
    • 10.2.2. Chart - Ex Vivo Growth
  • 10.3. In Vitro
    • 10.3.1. Table In Vitro - by Country
    • 10.3.2. Chart - In Vitro Growth

11. Gene Editing Markets - by Industry

  • 11.1. Pharma
    • 11.1.1. Table Pharma - by Country
    • 11.1.2. Chart - Pharma Growth
  • 11.2. Clinical
    • 11.2.1. Table Clinical - by Country
    • 11.2.2. Chart - Clinical Growth
  • 11.3. Academic
    • 11.3.1. Table Academic - by Country
    • 11.3.2. Chart - Academic Growth
  • 11.4. Contract
    • 11.4.1. Table Contract - by Country
    • 11.4.2. Chart - Contract Growth
  • 11.5. Other Industry
    • 11.5.1. Table Other Industry - by Country
    • 11.5.2. Chart - Other Industry Growth

12. Global Gene Editing Markets - by Product

  • 12.1. Instruments
    • 12.1.1. Table Instruments - by Country
    • 12.1.2. Chart - Instruments Growth
  • 12.2. Cells
    • 12.2.1. Table Cells - by Country
    • 12.2.2. Chart - Cells Growth
  • 12.3. Reagents
    • 12.3.1. Table Reagents - by Country
    • 12.3.2. Chart - Reagents Growth
  • 12.4. Other Product
    • 12.4.1. Table Other Product - by Country
    • 12.4.2. Chart - Other Product Growth

13. Appendices

  • 13.1. United States Medicare System: laboratory Fees Schedule
  • 13.2. The Most Used IVD Assays
  • 13.3. The Highest Grossing Assays
  • 13.4. Global Listing of Sequencing Establishments - Location & Contacts
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦